Ongoing important trials
PREDICT-Panc — transcriptomic signature–guided adjuvant chemo
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
- Phase
- Phase III
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT05314998
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Tumor gene-expression patterns are being studied to help choose post-surgery chemotherapy.
Why promising? Tests randomized personalization of adjuvant regimen using a transcriptomic signature.
What is not proven? Signature clinical benefit unproven; not a licensed test.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; recruiting (Heidelberg). No results yet.
Cancer / population: Pancreas — Rezeke PDAC
Intervention: TSS’ye göre oksaliplatin- veya gemsitabin-temelli adjuvan
Primary endpoint: DFS
Limitations: Sonuç yok; imza validasyonu kritik.